Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis

BACKGROUND: Animal studies reporting immune checkpoint inhibitors (CPIs) improved host defense and survival during bacterial sepsis provided one basis for phase I CPI sepsis trials. We performed a systematic review and meta-analysis examining the benefit of CPI therapy in preclinical studies, and wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Busch, Lindsay M., Sun, Junfeng, Cui, Xizhong, Eichacker, Peter Q., Torabi-Parizi, Parizad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000606/
https://www.ncbi.nlm.nih.gov/pubmed/32020483
http://dx.doi.org/10.1186/s40635-019-0290-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000606/
https://www.ncbi.nlm.nih.gov/pubmed/32020483
http://dx.doi.org/10.1186/s40635-019-0290-x

Ejemplares similares